advertisement
Virgili G 20
Showing records 1 to 20 | Display all abstracts from Virgili G100535 How Can We Quantify and Compare Harm in Surgical Trials?
Protasio JN
American Journal of Ophthalmology 2022; 241: 64-70
100204 Low-vision rehabilitation in Italy: Cross-sectional data from the Device and Aids Registry (D.A.Re)
Bartolomei F
European Journal of Ophthalmology 2022; 0: 11206721221091367
100646 Adverse Effects and Safety in Glaucoma Patients: Agreement on Clinical Trial Outcomes for Reports on Eye Drops (ASGARD)-A Delphi Consensus Statement
Thein AS; Hedengran A
American Journal of Ophthalmology 2022; 241: 190-197
100535 How Can We Quantify and Compare Harm in Surgical Trials?
King A
American Journal of Ophthalmology 2022; 241: 64-70
100204 Low-vision rehabilitation in Italy: Cross-sectional data from the Device and Aids Registry (D.A.Re)
Biagini I; Sato G
European Journal of Ophthalmology 2022; 0: 11206721221091367
100646 Adverse Effects and Safety in Glaucoma Patients: Agreement on Clinical Trial Outcomes for Reports on Eye Drops (ASGARD)-A Delphi Consensus Statement
Azuara-Blanco A
American Journal of Ophthalmology 2022; 241: 190-197
100535 How Can We Quantify and Compare Harm in Surgical Trials?
Pasquale LR; Barton K
American Journal of Ophthalmology 2022; 241: 64-70
100646 Adverse Effects and Safety in Glaucoma Patients: Agreement on Clinical Trial Outcomes for Reports on Eye Drops (ASGARD)-A Delphi Consensus Statement
Arita R
American Journal of Ophthalmology 2022; 241: 190-197
100204 Low-vision rehabilitation in Italy: Cross-sectional data from the Device and Aids Registry (D.A.Re)
Falchini E
European Journal of Ophthalmology 2022; 0: 11206721221091367
100646 Adverse Effects and Safety in Glaucoma Patients: Agreement on Clinical Trial Outcomes for Reports on Eye Drops (ASGARD)-A Delphi Consensus Statement
Cvenkel B
American Journal of Ophthalmology 2022; 241: 190-197
100204 Low-vision rehabilitation in Italy: Cross-sectional data from the Device and Aids Registry (D.A.Re)
Di Simone A
European Journal of Ophthalmology 2022; 0: 11206721221091367
100535 How Can We Quantify and Compare Harm in Surgical Trials?
Bonnar J; Qureshi R
American Journal of Ophthalmology 2022; 241: 64-70
100204 Low-vision rehabilitation in Italy: Cross-sectional data from the Device and Aids Registry (D.A.Re)
Mastrantuono C
European Journal of Ophthalmology 2022; 0: 11206721221091367
100646 Adverse Effects and Safety in Glaucoma Patients: Agreement on Clinical Trial Outcomes for Reports on Eye Drops (ASGARD)-A Delphi Consensus Statement
Gazzard G
American Journal of Ophthalmology 2022; 241: 190-197
100204 Low-vision rehabilitation in Italy: Cross-sectional data from the Device and Aids Registry (D.A.Re)
Micarelli S
European Journal of Ophthalmology 2022; 0: 11206721221091367
100646 Adverse Effects and Safety in Glaucoma Patients: Agreement on Clinical Trial Outcomes for Reports on Eye Drops (ASGARD)-A Delphi Consensus Statement
Heegaard S
American Journal of Ophthalmology 2022; 241: 190-197
100535 How Can We Quantify and Compare Harm in Surgical Trials?
Virgili G
American Journal of Ophthalmology 2022; 241: 64-70
100204 Low-vision rehabilitation in Italy: Cross-sectional data from the Device and Aids Registry (D.A.Re)
Virgili G
European Journal of Ophthalmology 2022; 0: 11206721221091367
100535 How Can We Quantify and Compare Harm in Surgical Trials?
Azuara-Blanco A
American Journal of Ophthalmology 2022; 241: 64-70
100646 Adverse Effects and Safety in Glaucoma Patients: Agreement on Clinical Trial Outcomes for Reports on Eye Drops (ASGARD)-A Delphi Consensus Statement
de Paiva CS; Petrovski G; Prokosch-Willing V; Utheim TP; Virgili G; Kolko M
American Journal of Ophthalmology 2022; 241: 190-197
